Browsing Institute of Population Health Sciences by Author "TACT2 Trial Management Group"
Now showing items 1-1 of 1
-
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
Velikova, G; Morden, JP; Haviland, JS; Emery, C; Barrett-Lee, P; Earl, H; Bloomfield, D; Brunt, AM; Canney, P; Coleman, R (2023-12)BACKGROUND: Adjuvant chemotherapy for patients with early breast cancer improves outcomes but its toxicity affects patients' quality of life (QOL). The UK TACT2 trial investigated whether accelerated epirubicin improves ...